Palantir Cofounder Backs US Monkey Farm Plan as AI Drives Up Macaque Prices

Accelerating drug discovery pipelines powered by artificial intelligence are colliding with severe supply bottlenecks for laboratory test subjects. Macaques, which are frequently used in medical experiments due to their biological similarities to humans, have seen prices skyrocket from roughly $3,000 in 2019 to upwards of $20,000 today. To counter this crunch, a startup called Safer Human Medicine is planning a massive domestic breeding facility backed by venture capitalist and Palantir cofounder Joe Lonsdale.

The proposed facility aims to house up to 30,000 monkeys, scaling its population gradually over a period of about two decades. Initial operations would rely on importing between 500 and 1,000 macaques from breeding facilities in Asia to kickstart domestic production. American laboratories currently import roughly 20,000 monkeys annually, leaving the research sector vulnerable to international supply chain disruptions and surging procurement costs.

The crunch stems from a combination of geopolitical shifts and biological constraints. China, which previously supplied about 60 percent of American laboratory monkey imports, halted exports in 2020. While labs subsequently turned to alternative suppliers like Cambodia, subsequent federal investigations uncovered issues regarding wild-caught animals being falsely labeled as captive-bred. Furthermore, female macaques do not reach reproductive maturity until roughly four years of age and typically produce only a single offspring each year, making rapid population scaling nearly impossible.

Meanwhile, the rapid proliferation of artificial intelligence in pharmaceutical research has only intensified the demand for animal test subjects. AI algorithms generate potential drug candidates much faster than traditional methods, meaning more compounds require rigorous toxicity and safety evaluations before entering human clinical trials. However, the domestic breeding initiative faces steep hurdles, including potential legal challenges and vocal opposition from animal welfare advocates who criticize the scale of the proposed primate facility.